First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

2012733 citationsJournal Article

Authors

Gefitinib failed to demonstrate superior OS compared with GP as first-line therapy for NSLAs.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 30, Issue 10, pp. 1122-1128

Field-Weighted Citation Impact: 71.73